Status:
UNKNOWN
S.P.PRO LIVER POWDER is Used to Improve Liver and Metabolic Indexes in People With Non-alcoholic Fatty Liver Disease
Lead Sponsor:
Taipei Medical University WanFang Hospital
Collaborating Sponsors:
Sheng Pu Pharmaceutics Co., Ltd.
Conditions:
Liver Diseases
Eligibility:
All Genders
35-75 years
Phase:
PHASE4
Brief Summary
With the Westernization of the diet and insufficient exercise, Taiwan's population of obesity, diabetes, and hyperlipidemia has increased in recent years, and the prevalence of the non-alcoholic fatty...
Detailed Description
With the Westernization of the diet and insufficient exercise, Taiwan's population of obesity, diabetes, and hyperlipidemia has increased in recent years, and the prevalence of the non-alcoholic fatty...
Eligibility Criteria
Inclusion
- Patients with fatty liver diagnosed by abdominal ultrasound or hepatic fibrometer within half a year's data
- Subjects with the non-alcoholic fatty liver disease
- The severity of fatty liver should be at least 3 points by taking an abdominal ultrasound
Exclusion
- Female patients are pregnant or breastfeeding.
- Patients with viral hepatitis.
- Long-term drinkers.
- Those who use slimming products and vitamin E.
Key Trial Info
Start Date :
January 13 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2021
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04718051
Start Date
January 13 2021
End Date
December 31 2021
Last Update
January 22 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wanfang Hospital
Taipei, Wenshan District, Taiwan, 116